Marshall Wace, LLP Spectrum Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.63 - $1.59 $610,536 - $1.54 Million	-969,105 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.42 $1.23 Million - $2.35 Million	969,105 New	969,105 $1.23 Million
Q3 2019 Nov 14, 2019	SELL	$7.03 - $9.7 $2.23 Million - $3.07 Million	-316,970 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.36 - $11.26 $2.33 Million - $3.57 Million	316,970 New	316,970 $2.73 Million
Q1 2019 May 14, 2019	SELL	$9.08 - $11.84 $81,175 - $105,849	-8,940 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$6.39 - $16.99 $704,408 - $1.87 Million	-110,236 Reduced 92.5%	8,940 $78,000
Q3 2018 Nov 14, 2018	BUY	$16.52 - $24.82 $1.97 Million - $2.96 Million	119,176 New	119,176 $2 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.